Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM5XUQL)

Drug Name
CPI-613 Drug Info
Synonyms
CPI-613; 95809-78-2; 6,8-bis(benzylthio)octanoic acid; CPI 613; MLS006010202; SCHEMBL1062218; 6,8-Bis(benzylsulfanyl)octanoic acid; Octanoic acid, 6,8-bis((phenylmethyl)thio)-; Octanoic acid, 6,8-bis[(phenylMethyl)thio]-; 6,8-Bis[(phenylmethyl)thio]octanoic acid; CPI613; CHEMBL3186849; QCR-193; AOB1058; MolPort-023-219-128; HMS3656L06; C22H28O2S2; BCP04663; EX-A2043; s2776; AKOS025142095; BCP9000552; DB12109; RL06062; CS-0961; NCGC00344764-01; SMR004701300; AS-16613; BC261916; AK174899; HY-15453; BCP0726000030; KB-293127; AB0035874
Cross-matching ID
PubChem CID
24770514
CAS Number
CAS 95809-78-2
TTD Drug ID
D07NVI

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Epithelial cell signaling in Helicobacter pylori infect... 1.82 1.99e-1 62/70 (88.57%) CXCL8;MAPK13;PAK1;...
Proteasome 1.77 1.64e-1 44/46 (95.65%) PSMB3;POMP;PSMD14;...
Antigen processing and presentation 1.77 1.29e-1 60/78 (76.92%) IFI30;HSPA2;HLA-DQA1;...
RNA transport 1.75 9.97e-2 128/186 (68.82%) EIF2S3;NMD3;NUP37;...
IL-17 signaling pathway 1.73 8.68e-2 84/94 (89.36%) CXCL8;MAPK13;IL17RB;...
Pentose phosphate pathway 1.72 7.62e-2 25/30 (83.33%) PFKL;PGD;TALDO1;...
Type I diabetes mellitus 1.71 7.20e-2 38/43 (88.37%) HSPD1;HLA-DQA1;HLA-B;...
Cell cycle 1.65 1.16e-1 110/124 (88.71%) E2F2;CDKN1B;MAD2L1;...
Mismatch repair 1.64 1.09e-1 22/23 (95.65%) MSH2;RFC5;EXO1;...
Non-homologous end-joining 1.63 1.13e-1 11/13 (84.62%) DNTT;DCLRE1C;RAD50;...
Cellular senescence 1.61 1.17e-1 139/156 (89.1%) E2F2;CXCL8;MAPK13;...
Nucleotide excision repair 1.61 1.10e-1 40/47 (85.11%) CETN2;RAD23B;RFC5;...
Glycolysis / Gluconeogenesis 1.60 1.19e-1 56/67 (83.58%) PFKL;ALDH3A1;PGK1;...
GABAergic synapse 1.58 1.35e-1 76/89 (85.39%) GLUL;GABRP;GNAI1;...
Fructose and mannose metabolism 1.56 1.49e-1 30/33 (90.91%) AKR1B10;PFKFB3;PFKL;...
DNA replication 1.56 1.44e-1 34/36 (94.44%) RFC5;POLE2;SSBP1;...
Galactose metabolism 1.54 1.63e-1 26/31 (83.87%) AKR1B10;PFKL;UGP2;...
Central carbon metabolism in cancer 1.53 1.60e-1 67/70 (95.71%) FGFR3;SLC2A1;PFKL;...
Collecting duct acid secretion 1.50 2.04e-1 22/27 (81.48%) SLC4A1;ATP6V1D;ATP6V1B2;...
Alanine, aspartate and glutamate metabolism 1.50 1.96e-1 27/37 (72.97%) GLUL;ALDH5A1;GLS;...
Neomycin, kanamycin and gentamicin biosynthesis 1.50 1.88e-1 5/5 (100%) HK2;HK3
Parkinson disease 1.48 2.09e-1 176/249 (70.68%) UCHL1;TUBB2A;SNCA;...
Citrate cycle (TCA cycle) 1.48 2.06e-1 30/30 (100%) DLST;DLD;IDH2;...
Bladder cancer 1.46 2.11e-1 40/41 (97.56%) E2F2;FGFR3;CXCL8;...
Melanogenesis 1.45 2.22e-1 74/101 (73.27%) TYRP1;WNT5A;GNAI1;...
Vibrio cholerae infection 1.43 2.21e-1 44/50 (88%) SLC12A2;ATP6V1D;ACTB;...
Gastric acid secretion 1.43 2.14e-1 63/76 (82.89%) GNAI1;ACTB;GNAI3;...
Long-term potentiation 1.41 2.21e-1 61/67 (91.04%) KRAS;MAPK1;RAP1B;...
Glyoxylate and dicarboxylate metabolism 1.41 2.18e-1 23/30 (76.67%) GLUL;DLD;MDH1;...
Nitrogen metabolism 1.40 2.24e-1 16/17 (94.12%) GLUL;GLUD2;CA2;...
alpha-Linolenic acid metabolism -1.22 4.56e-1 17/25 (68%) PLA2G1B;PLA2G12A;PLA2G2D;...
AGE-RAGE signaling pathway in diabetic complications -1.22 4.55e-1 97/100 (97%) MMP2;PIK3CA;EGR1;...
Legionellosis -1.23 4.63e-1 51/57 (89.47%) IL1B;CASP9;CD14;...
Calcium signaling pathway -1.27 4.31e-1 213/240 (88.75%) FGF20;HRC;ADCY2;...
Colorectal cancer -1.28 4.35e-1 84/86 (97.67%) ARAF;PIK3CA;CASP9;...
Rap1 signaling pathway -1.29 4.25e-1 184/210 (87.62%) ITGA2B;FGF20;PRKCI;...
Sphingolipid metabolism -1.29 4.22e-1 32/49 (65.31%) NEU1;SMPD3;GALC;...
Glycerophospholipid metabolism -1.30 4.03e-1 71/98 (72.45%) DGKD;PEMT;PLPP2;...
Relaxin signaling pathway -1.30 4.15e-1 114/129 (88.37%) PRKACB;MAP2K7;MMP13;...
Transcriptional misregulation in cancer -1.31 4.15e-1 158/192 (82.29%) JMJD1C;NFKB1;RARA;...
Regulation of lipolysis in adipocytes -1.32 4.03e-1 52/55 (94.55%) ADCY2;PTGS1;ADRB2;...
Focal adhesion -1.32 4.21e-1 180/201 (89.55%) MET;SRC;ACTN4;...
Phospholipase D signaling pathway -1.32 4.28e-1 134/148 (90.54%) RALA;AGT;ADCY2;...
N-Glycan biosynthesis -1.32 4.48e-1 38/50 (76%) DPAGT1;B4GALT1;ST6GAL1;...
Viral protein interaction with cytokine and cytokine re... -1.33 4.49e-1 84/100 (84%) CCL23;TNFRSF10B;CXCR5;...
Cortisol synthesis and secretion -1.35 4.06e-1 58/65 (89.23%) CREB5;CACNA1G;HSD3B1;...
Yersinia infection -1.37 3.76e-1 120/137 (87.59%) ARPC4;TNF;MAP2K7;...
Dilated cardiomyopathy -1.39 3.62e-1 86/96 (89.58%) ITGA2B;AGT;ADCY2;...
Caffeine metabolism -1.40 3.46e-1 5/6 (83.33%) XDH;CYP2A6;NAT1
ABC transporters -1.40 3.70e-1 37/45 (82.22%) ABCC9;ABCD4;ABCB8;...
Cytosolic DNA-sensing pathway -1.42 3.69e-1 52/63 (82.54%) POLR1C;POLR3E;POLR3C;...
Bacterial invasion of epithelial cells -1.42 3.79e-1 59/77 (76.62%) DNM2;ARPC4;HCLS1;...
Amoebiasis -1.44 3.75e-1 99/102 (97.06%) LAMB2;LAMA2;ACTN1;...
Toll-like receptor signaling pathway -1.45 3.63e-1 94/104 (90.38%) PIK3CA;TLR8;IFNAR2;...
Proteoglycans in cancer -1.48 3.22e-1 172/205 (83.9%) PLCE1;LUM;CD44;...
Cytokine-cytokine receptor interaction -1.53 2.41e-1 246/295 (83.39%) CXCR3;TNFSF12;CCR1;...
Glycosaminoglycan biosynthesis -1.55 2.42e-1 40/58 (68.97%) NDST4;NDST2;EXT2;...
Ascorbate and aldarate metabolism -1.55 2.82e-1 15/30 (50%) GUSB;ALDH3A2;UGDH;...
Hematopoietic cell lineage -1.55 3.30e-1 90/99 (90.91%) IL1A;CD37;CD1D;...
Chagas disease -1.56 3.98e-1 93/102 (91.18%) IL1B;GNA11;TNFRSF1A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 3.33uM 24H